1. AN ORGANIZATION STUDY
GLAXOSMITHKLINE
Presented by:-
Mr. Mehsum Ali
Mr. Ali Ather Mohsin
Mr.Mohammad Arif
Mr. Taj-ud-din
Mr. Muhammad Ali Hashmi

2.  Introduction and Background
 Vision and Mission
 Product line
 GSK Management
 Organizational Chart
 Management Levels
 SWOT Analysis
 Porter’s Strategies
 Questions and Answers

3.  GlaxoSmithKline plc (LSE: GSK NYSE: GSK),
often abbreviated to GSK, is a global
pharmaceutical, biologics, vaccines and consumer
healthcare company headquartered in London,
United Kingdom. It is the world's Fourth largest
pharmaceutical company measured by revenues
(after Johnson & Johnson, Pfizer & Roche.
 GSK was formed in 2000 by the merger of
GlaxoWellcome plc (formed from the acquisition
of Wellcome plc by Glaxo plc), and SmithKline
Beecham plc (from the merger of Beecham plc,
and SmithKlineBeckman Corporation).

4.  GlaxoSmithKline Pakistan Limited came into
existence after the merger of Smith Kline and
French of Pakistan Limited and Beecham
Pakistan (Private) Limited with Glaxo Wellcome
Pakistan Limited in 2002. It is listed on the
Karachi and Lahore stock exchanges. GSK has a
large portfolio of products ranging tablets,
toothpaste, inhalers and complex capsules in over
28,000 different pack sizes and presentations.

5. “The opportunity to make a
difference to the lives of billions
of people”.
 GlaxoSmithKline has a challenging
and inspiring mission their mission
is to improve the quality of human
life by enabling people to do more,
feel better and live longer

7.  The company is managed by the Board of
Directors and the Corporate Executive Team.
 The Board is comprised of executive and non-
executive directors who are responsible for their
corporate governance and ultimately accountable
for their activities, strategy and performance.
 The Chief Executive Officer (CEO) is responsible
for the management of the business and is
assisted by the Corporate Executive Team that
manages their activities. Each member is
responsible for a specific part of the business.

8. ORGANIZATIONAL CHART

9. The management levels of GSK
are as follows:-
Executive-Level
 Director-Level
 Manager-Level
 Staff

11. Strengths: Weaknesses:
No online presence in Pakistan
Strong Management Team Strong focus on UK market (losing
Large Market Share
opportunities in Pakistan)
Highest research Products in Pakistan Less checking on the sales
Wide range of Products
representatives for their working in
field
Opportunities: Threats:
Emerging markets and expansion Lower cost competitors or imports like
abroad Chinese and Indian medicines etc
Have great chance to cash its brand Patent expiry on drugs that generate
name in the field of surgical market strong income
GSK can be able to cash its name in Increasing cost of drug trials (research)
baby foods and ever higher standards imposed by
national drug approvals bodies.

13.  TO GROW A DIVERSIFIED GLOBAL BUSINESS.
 DELIVER VALUE PRODUCTS
 SIMPLIFYING THE OPERATING MODEL
 CHALLENGING AND INSPIRING MISSION
 LONG TERM INCENTIVE PLAN

14.  Increase growth in the pharmaceutical business
in its core market.
 GSK is diversifying its business to bring balance
in product portfolio & go away from a reliance on
traditional markets.
 GSK expects to generate future sales growth by
strengthening its core pharmaceutical business &
supplementing it with increased investment in
growth such as; vaccines, dermatology and
consumer health care.
 Business expansion inn Japan
 Build a leadership in dermatology.

15.  Focusing on the best science
 Focus on research and development
 Diversifying the level of externalization in
research to focus on disease area, where GSK
believe the prospects for successful registration
and launch of differentiated medicines.

16.  As GSK continue to change shape, so it is
essential that reduce the complexities in
operating model, improve efficiencies and reduce
cost.
 Re-shape manufacturing

17.  GSK has a challenging vision and mission is to
improve the quality of human life by making
people to do more, feel better and live longer.

18.  Long term incentive plan.
awards are made to executives under the
following long term incentive plan,
i) Deferred annual bonus plan
iv) Performance share plan
Explanation: Deferred Annual bonus plan:
The deferred annual bonus plan
encourages long term shareholding, discourages
excessive risk taking and help focus on GSK’S
key strategic priorities.

19.  Performance share : the performance share plan
ensure focus on the delivery of GSK’S strategic
priorities and long term share holders returns
relative to other pharmaceutical companies.

20.  Meeting with DR. AHMED FARHAN
 Questionnaire MANAGER AND STAFF
 Interview DR. AHMED FARHAN

21.  GSK annual report 2011.
 www.gsk.com
 Term report of GSK
 Wikipedia,2011